Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.950-5.350 for the period, compared to the consensus estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Stock Up 5.0 %

Shares of NASDAQ:HALO opened at $53.76 on Friday. The business has a 50-day moving average price of $50.16 and a 200 day moving average price of $54.00. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24.

Analyst Ratings Changes

A number of equities analysts recently weighed in on HALO shares. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. HC Wainwright restated a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research note on Monday, December 30th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Finally, Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.